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The first Italian Meeting Course on Laminopathies 
entitled “Laminopathies: many diseases, one gene” was 
held in Bologna on April 8-9, 2011 and it was attended by 
100 participants, including neurologists, dermatologists, 
cardiologists, biologists, geneticists, and physiotherapists 
besides patients and families Associations. This meeting 
was organized by the Institute of Molecular Genetics of 
the National Research Council, the Italian Network for 
Laminopathies and the AIProSaB, the Italian association 
for the study of Hutchinson-Gilford progeria.
The main aim of the meeting was to join scientists 
involved in clinical practise and research on lamin A/C 
linked diseases (1) and to offer an overview on current 
clinical protocols and medical research to clinicians, re-
searchers and patients.
The meeting focused on the following main areas: 
1) the biology of the nucleus and the nuclear envelope 
and the biological pathways affected in laminopathies; 
2)  the  epidemiology  of  muscle  laminopathies,  lipod-
ystrophies  and  progeroid  syndromes;  3)  the  Emery-
Dreifuss Muscular dystrophy (EDMD) from a clinical 
point  of  view;  4)  Dilated  cardiomyopathy  with  con-
duction defects (CMD-CD) from diagnosis to therapy; 
5) Familial partial lipodystrophy of the Dunningan type 
(FPLD): diagnosis and therapy; 6) Progeroid laminopa-
thies, including mandibuloacral displasia (MADA) and 
Hutchinson-Gilford  progeria  (HGPS):  diagnosis  and 
therapeutic trials.
Biology of the cell nucleus  
and pathogenetic pathways  
in laminopathies
The first day of the meeting was devoted to an in-
troduction to the biology of the cell nucleus (2). New 
insights into the understanding of nuclear functionality 
have been presented. The nucleus is now considered a 
complex  interaction  platform,  where  proteins  regulate 
nucleo-cytoskeleton interplay in view of chromatin or-
ganization and transcriptional activity (Nadir M. Maraldi, 
Bologna).
The  main  pathogenetic  pathways  in  lamina  A/C-
linked  disorders  have  been  reviewed.  Altered  mecha-
nosignaling  transduction,  chromatin  modulation  and 
differentiation-related gene transcription (3, 4) have been 
highlighted as the key events at the basis of laminopathic 
diseases. Prelamin A accumulation (5) has been reported 
as the main molecular defect in systemic and adipose tis-
sue laminopathies (Cristina Capanni, Bologna).
Epidemiology of lamin-linked 
diseases
Muscle laminopathies, including EDMD, LGMD1B 
and CMD-DC, are transmitted by dominant inheritance 
or may occur due to spontaneous mutations. The clini-
cal phenotype (6) is characterized by joint contractures, 
muscle  weakness  and  wasting  and  cardiac  conduction 
defects, most of them evolving to pictures of dilated car-
diomyopathy. The epidemiology of muscle laminopathies 
is complex and as yet not well defined. The incidence 
of autosomal dominant EDMD caused by mutations in 
lamin A/C gene (Enrico Bertini, Rome) has been report-
ed as extremely variable, ranging from 1 to 3:100.000. 
Lipodystrophies may be caused by mutations in several 
genes including PPARgamma, LMNA, AKT and seipin 
gene or also acquired, such as it happens in 40 percent of 
HIV infected patients undergoing anti-retroviral therapy. 
An overview of these disorders has been presented, with 
particular emphasis on LMNA-associated familial partial 
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Emery-Dreyfuss muscular dystrophy (1°)
Child with normal psycho-intellectual development
  Floppy infant    Motor retardation   Rigid rachis    Muscle
        Falling head    Toe walker    weakness
              Retractions
 
 
  Medical history         Clinical suspect of    CPK + ECG
  for cardiomyopathy      muscolar      (normal findings
  arhythmic events/       laminopathy      do not exclude)
  Sudden death 
  (negativity does 
  not exclude)
Suggest a specialised center for MNM
  Clinical-anamnestic         Muscular  EMG    Muscle
  re-evaluation      ±    MRI    EMG    biopsy
  Clinical-instrumental confirmation          DNA analysis
Emery-Dreyfuss muscular dystrophy (2°)
Specialised center for NMD: Clinical-anamnestic re-evaluation evocative clinical phenotype
                 CPK
  Muscular RM  evaluate   Normal    Hight  evaluate   Muscular RM
  ENG ± EMG                ENG ± EMG
          Muscle biopsy: istoenzymatic 
          and immunohistochemistry study 
          (dystrophin, sarcoglycan, merosin, alpha-dystroglycan, 
          collagen VI, WB calpain)
 
  Genetic    Normal        Positive DNA analysis
  analysis:   immune       DIAGNOSIS
  LMNA    system
  Positive: laminopathy diagnosis      Negative
  Familial screening with ECG-echocariogram
Figures 1 and 2.. Flow chart for diagnosis and follow-up of Emery-Dreifuss muscular dystrophy.G. Lattanzi et al.
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lipodystrophy, the most represented form of the disease 
(Renato Pasquali, Bologna). Progeroid syndromes linked 
to mutations in several genes including LMNA have been 
reviewed (Claudio Franceschi, Bologna).
Genotype-phenotype correlation  
in laminopathies
During the second day, the lecture held by Giuseppe 
Novelli (Rome) focused on the genotype-phenotype cor-
relation in laminopathies.
Beside mutations in the LMNA gene that give rise 
to  eight  different  laminopathic  phenotypes,  other  dis-
eases are linked to mutations in lamin A-related proteins, 
namely the ZMPSTE24 endoprotease, which catalyses 
prelamin A maturation, the nuclear envelope constituents 
emerin, nesprin 1 and 2 and BAF, the lamina-associated 
protein LAP2alpha, which interact with lamin A/C, chro-
matin and cytoskeleton proteins. The clinical phenotype 
of each laminopathy has been described in relationship 
with mutations in the lamin A/C gene. The high degree of 
interfamilial and intrafamilial variability in clinical sever-
ity observed among patients (7), possibly due to modifier 
loci or allelic differences, takes it difficult to correlate the 
genotype with the phenotype.
Emery-Dreifuss Muscular 
Dystrophy
The  clinical  spectrum  of  laminopathies  was  dis-
cussed with a special emphasis on the tissue-specificity 
of the various laminopathies and the overlapping clinical 
features (8). A detailed analysis of diagnostic protocols 
for EDMD, Limb-Girdle muscular dystrophy type 1B and 
congenital LMNA-linked muscular dystrophy (9-13) has 
been presented by Tiziana Mongini, Eugenio Mercuri, 
Lucia Morandi, Antonella Pini, Stefano Previtali, Nicola 
Carboni and Adele D’Amico. Mercuri and D’Amico de-
scribed the Dropped Head Syndrome in young patients 
affected by EDMD, which they suggest to consider it as 
a clinical sign of laminopathy. Mongini and Carboni re-
ported mild phenotypes of EDMD, even in aged patients 
with minimal contractures and difficulty in climbing stairs 
or  in  patients  undergoing  muscle  biopsy  for  different 
causes such as hyperCKemia or myalgias in the course of 
therapy with statin, a widely used anticholesterol agent. 
Morandi reported typical aspects of histochemistry and 
immunohisto-chemistry in biopsies from EDMD patients, 
showing different phenotype depending on the affected 
muscle. Pini presented the flow-chart for diagnosis and 
follow-up of children with EDMD (Figs. 1, 2).
Dilated cardiomyopathy with 
conduction defects
A special emphasis was made on the cardiac dis-
eases (14, 15) with the aim to give recommendations 
for clinical management of these disorders and the use 
of implantable devices. Elena Biagini reviewed the car-
diac  phenotype  of  laminopathies  and  highlighted  the 
existence of undiagnosed cases, especially in patients 
followed in standard cardiological units. Luisa Politano 
underlined that patients with mutations in LMNA gene 
presented an increased risk of cardiac sudden death and 
reported the flow-chart for diagnosis and fundamental 
clinical follow-up of patients with CMD-DC (Fig. 3); 
Giuseppe Boriani presented the advantages and the risk 
to benefit ratio of new implantable cardioverter defi-
brillators in CMD-CD and/or EDMD patients suffering 
from  conduction  defects,  although  yet  asymptomatic. 
Roberta Poletti presented new imaging techniques for 
the early diagnosis of fibrosis in the heart of lamino-
pathic patients.
progeroid laminopathies and 
familial partial lipodystrophy. 
Future trial developments
The new perspectives for the treatment of laminopa-
thies affecting adipose tissue and/or causing premature 
ageing have been presented. Paolo Sbraccia presented 
the clinical features and the outcome of the first clini-
cal trial performed in MADA (16) by the use of statins 
and bisphosphonates. Alessandra Gambineri presented 
the flow-chart for diagnosis and follow-up of familial 
partial lipodystrophy (Fig. 4) and the efficacy of piogli-
tazone treatment in patients with metabolic disturban-
cies.  Emanuela  Scarano  presented  the  flow-chart  for 
diagnosis and follow-up of patients affected by HGPS 
(Fig. 5) and the clinical outcome in a patient undergo-
ing a clinical trial using statins and bisphosphonates. 
Cardiac laminopathy
• Cardiology visit
• Standard ECG (12 derivations)
• 24-hour dynamic ECG according to Holter
• Echocardiogram with echocolordoppler and 
   acoustics densitometry
• Electrophysiological study (EFS) when indicated
• PMK/ICD implant
Figure 3. Flow chart for diagnosis and follow-up of car-
diac laminopathy.Laminopathies: many diseases, one gene. Report of the first Italian Meeting Course on Laminopathies
141
Giovanna Lattanzi presented new experimental thera-
peutical approaches for laminopathies affecting bone, 
such as MADA and HGPS, by the use of drugs limit-
ing the levels of cytochines (TGFbeta 2 and osteoprote-
gerin) (17), and the rationale of therapies based on the 
use of statins and bisphosphonates. Further, recent data 
showing decline of IGF1 levels in models of progeroid 
laminopathies (18) have been reported as a suggestion 
for new pathogenetic mechanisms and/or new therapeu-
tic perspectives.
patients’ contribution
Patients, affected by progeria or EDMD2, have pre-
sented their experiences and their point of view on di-
agnosis, follow-up and treatment of diseases. They sug-
gested closer interplay among clinicians, researchers and 
patients and were in favour of the website as a way of 
information for family doctors and patients to improve di-
agnostic approach and follow-up. They also encouraged 
the research activity.
Conclusions
Animate  discussions  during  this  meeting  clarified 
different  points  of  view,  and  constructively  resulted 
in a proposal for specific guidelines and flow-charts in 
laminopathies. The inter-disciplinary approach to lami-
nopathic disorders was highly encouraged. This was an 
enjoyable and fruitful workshop that will lead to new 
collaborations into the network (https://www.igm.cnr.it/
index.php?id=383) and will contribute significantly to the 
improvement of future therapeutic perspectives in lamin-
opathies.
Figure 4. Flow chart for diagnosis and follow-up of FPLD2.
Familial partial lipodystrophy (FPLD2)
• Distribution of adipose tissue. SC adipose tissue?
• Muscular hypertrophy?
• Familiarity?
• Strong insulin resistance – if yes: increased 
   probability
• Hepatic steatosis/Dyslipidemia – if yes: increased
   probability
• Leptin and adiponectin measurement
• Qualifying fat mass (DEXA)
Metabolic laminopathy
HGPS MAD APS FPLD2
Measurement PA
Metabolism:
hepatic
lipid
glucose
Ca-P
Abdominal echography
Food survey
Personalised diet
Skeletal system
osteography
densitometry
Cutaneous system
dermatologic visit
Cardiovascular system
ECG, Echocardiography
Odontoiatric system
odontoiatric examination
Measurement PA
Metabolism:
hepatic
lipid
glucose
Ca-P
Abdominal echography
Food survey
Personalised diet
Skeletal system
skeletal X-ray
delayed closure of cranial 
bones
wormian bones, hypoplasia,
limbs (4-5 aa) and clavicle
osteolysis
osteography
densitometry
Cutaneous system
dermatologic visit
Cardiovascular system
ECG
Odontoiatric system
odontoiatric examination
Measurement PA
Metabolism:
hepatic
lipid
glucose
Ca-P
Abdominal echography
Food survey
Personalised diet
Skeletal system
X-ray for hands, feet, chest
no osteolysis
osteography
densitometry
Cutaneous system
dermatologic visit
Cardiovascular system
ECG
Odontoiatric system
odontoiatric examination
auditory system:
audiometric evaluation
(after 20 years)
Measurement PA
Metabolism:
hepatic
lipid
glucose
Ca-P
Abdominal echography
Food survey
Personalised diet
Cutaneous system
dermatologic visit
Cardiovascular system
ECG
Echocardiography
LMNA and/or ZMPSTE24 analysis the follow-up type and a possible therapeutic approach must be decided 
on the bases of the clinical phenotype for each case
Figure 5. Flow-chart for the follow-up of metabolic laminopathies.G. Lattanzi et al.
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